RxDoctor Payments Data

Danielle Englert Doggett, MD

Neurology · Charlotte, NCNPI 1205049533

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $162,095 of the $214,589 with a category attached, or 75.5%. Boston Scientific accounts for 86.5% of it on its own, with 9 other manufacturers making up the rest. Among neurology clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$214,589in general payments, 2019–2025

Across 335 payments — averaging $640.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$186K
  • Acorda Therapeutics, Inc$11K
  • Teva Pharmaceuticals USA, Inc.$10K
  • Adamas Pharmaceuticals, Inc.$3K
  • AbbVie$2K
  • Kyowa Kirin, Inc.$2K
  • plus $1K from 4 others

What the payments were for

  • Consulting fees$21,41010%
  • Speaking & faculty fees$162,09576%
  • Travel & lodging$24,71912%
  • Food & beverage$6,1553%
  • Education$2100%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$214,589 in reported general payments places this provider in the 95th percentile of 566 neurology providers in North Carolina.

See all neurology providers in North Carolina

Medicare billing

Part B allowed, 2024
$97,349
Medicare patients
342
Services billed
1,291

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine97$969,630
GocovriAmantadine Hcl130$449,868
NuplazidPimavanserin Tartrate71$384,344
IngrezzaValbenazine Tosylate19$151,655
RytaryCarbidopa/Levodopa122$148,931
NeuproRotigotine37$48,493
Carbidopa-LevodopaCarbidopa/Levodopa1,077$41,250
Carbidopa-Levodopa ErCarbidopa/Levodopa430$28,185
Rasagiline Mesylate198$23,565
NourianzIstradefylline12$22,202
Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone42$21,303
AmantadineAmantadine Hcl256$16,173
Ropinirole ErRopinirole Hcl44$11,489
Selegiline Hcl80$9,433
Entacapone31$8,670

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$9,634$969,63097 claims
Acadia Pharmaceuticals IncNuplazid$1,077$384,34471 claims
Kyowa Kirin, Inc.Nourianz$1,737$22,20212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 566 neurology providers in North Carolina.

Other neurology in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →